Stockreport

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Tenaya Therapeutics, Inc.  (TNYA) 
PDF Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 Trial of TN-201 Gene Therapy Initial TN-201 [Read more]